1502 related articles for article (PubMed ID: 31112379)
1. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
3. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
Distler O; Brown KK; Distler JHW; Assassi S; Maher TM; Cottin V; Varga J; Coeck C; Gahlemann M; Sauter W; Schmidt H; Highland KB;
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):75-81. PubMed ID: 28664834
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L; du Bois RM; Raghu G; Azuma A; Brown KK; Costabel U; Cottin V; Flaherty KR; Hansell DM; Inoue Y; Kim DS; Kolb M; Nicholson AG; Noble PW; Selman M; Taniguchi H; Brun M; Le Maulf F; Girard M; Stowasser S; Schlenker-Herceg R; Disse B; Collard HR;
N Engl J Med; 2014 May; 370(22):2071-82. PubMed ID: 24836310
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR; Wells AU; Cottin V; Devaraj A; Walsh SLF; Inoue Y; Richeldi L; Kolb M; Tetzlaff K; Stowasser S; Coeck C; Clerisme-Beaty E; Rosenstock B; Quaresma M; Haeufel T; Goeldner RG; Schlenker-Herceg R; Brown KK;
N Engl J Med; 2019 Oct; 381(18):1718-1727. PubMed ID: 31566307
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
Azuma A; Chung L; Behera D; Chung M; Kondoh Y; Ogura T; Okamoto M; Swarnakar R; Zeng X; Zou H; Meng X; Gahlemann M; Alves M; Kuwana M;
Respir Investig; 2021 Mar; 59(2):252-259. PubMed ID: 33223487
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
9. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.
Maher TM; Mayes MD; Kreuter M; Volkmann ER; Aringer M; Castellvi I; Cutolo M; Stock C; Schoof N; Alves M; Raghu G;
Arthritis Rheumatol; 2021 Apr; 73(4):671-676. PubMed ID: 33142016
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial.
Kuwana M; Ogura T; Makino S; Homma S; Kondoh Y; Saito A; Ugai H; Gahlemann M; Takehara K; Azuma A
Mod Rheumatol; 2021 Jan; 31(1):141-150. PubMed ID: 32243207
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
12. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
Maher TM; Bourdin A; Volkmann ER; Vettori S; Distler JHW; Alves M; Stock C; Distler O
Respir Res; 2022 Jul; 23(1):178. PubMed ID: 35790961
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
Kuwana M; Azuma A
Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
[TBL] [Abstract][Full Text] [Related]
14. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Seibold JR; Maher TM; Highland KB; Assassi S; Azuma A; Hummers LK; Costabel U; von Wangenheim U; Kohlbrenner V; Gahlemann M; Alves M; Distler O;
Ann Rheum Dis; 2020 Nov; 79(11):1478-1484. PubMed ID: 32759258
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Kolb M; Raghu G; Wells AU; Behr J; Richeldi L; Schinzel B; Quaresma M; Stowasser S; Martinez FJ;
N Engl J Med; 2018 Nov; 379(18):1722-1731. PubMed ID: 30220235
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Richeldi L; Costabel U; Selman M; Kim DS; Hansell DM; Nicholson AG; Brown KK; Flaherty KR; Noble PW; Raghu G; Brun M; Gupta A; Juhel N; Klüglich M; du Bois RM
N Engl J Med; 2011 Sep; 365(12):1079-87. PubMed ID: 21992121
[TBL] [Abstract][Full Text] [Related]
18. Interstitial lung disease in patients with systemic sclerosis: what can we learn from the SENSCIS trial?
Assassi S; Tumuluri S; Levin RW
Clin Exp Rheumatol; 2023 Aug; 41(8):1713-1719. PubMed ID: 37534955
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
Inoue Y; Suda T; Kitamura H; Okamoto M; Azuma A; Inase N; Kuwana M; Makino S; Nishioka Y; Ogura T; Takizawa A; Ugai H; Stowasser S; Schlenker-Herceg R; Takeuchi T
Respir Med; 2021 Oct; 187():106574. PubMed ID: 34564020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]